Neuroscience

Free Version

Upgrade subject to access all content

Moderate

Signaling Cascade Downstream of Dopamine Receptor Activation

NEURO-JBFCC3

D1 and D5 dopamine receptors are coupled to the $G_s$ subtype of G-proteins. Pharmacological inhibition of dopamine receptors D1/D5 in the medial prefrontal cortex (mPFC) causes attention deficit and hyperactivity.

Changes in gene expression are necessary for the appearance of attention deficit and hyperactivity symptoms upon inhibition of D1/D5 receptors. These changes in gene expression are caused by transcription factor cAMP response element binding protein (CREB). Rp-cAMPS is a cell permeable drug that inhibits PKA.

What effects of Rp-cAMPS microinjection into mPFC do you expect to see?

A

Increased phosphorylation of CREB and hypoactivity.

B

Changes in gene expression consistent with activation of CREB and hypoactivity.

C

Reduced phosphorylation of CREB, attention deficit and hyperactivity.

D

No change in CREB phosphorylation, attention deficit and hyperactivity.